A. Mokatrin

发表

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

H. Kohrt, P. Hegde, R. Herbst, 2014, Nature.

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Keunchil Park, J. Mazières, J. Vansteenkiste, 2015 .

A Modified Enzyme-Linked Immunosorbent Assay for Measurement of Antibody Responses to Meningococcal C Polysaccharide That Correlate with Bactericidal Responses

B. Plikaytis, G. Carlone, D. Granoff, 1998, Clinical Diagnostic Laboratory Immunology.

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

R. Sullivan, K. Flaherty, J. Sosman, 2013 .

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

R. Herbst, S. Gettinger, J. Soria, 2013 .

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

T. Powles, J. Sosman, M. Sznol, 2013 .

Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction

T. Kinoshita, M. Crowther, A. Mokatrin, 2020, Hematology.

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

J. Sosman, F. Hodi, S. Gettinger, 2013 .

Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC).

S. Gettinger, C. Chappey, F. Kabbinavar, 2014 .

BIOCINE® MENINGOCOCCAL C (MenC) CONJUGATE VACCINE ELICITS HIGH TITERS OF SERUM BACTERICIDAL ACTIVITY IN TODDLERS. ▴ 1053

D. Granoff, S. Halperin, N. MacDonald, 1996, Pediatric Research.

MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine

D. Granoff, A. Mokatrin, G. Van Nest, 1997, Infection and immunity.

Evaluation of oral Ro70-0004/003, an α1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction

A. Mokatrin, D. Gennevois, D. Blue, 2001, International Journal of Impotence Research.

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

J. Sosman, R. Herbst, F. Hodi, 2013 .

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study

D. Miklos, I. Yakoub-Agha, B. Ko, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma

K. Rogers, T. Siddiqi, S. Coutre, 2022, Leukemia & lymphoma.

Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies

J. Gribben, I. Flinn, T. Kipps, 2018, American journal of hematology.

901-82 A Multicenter Controlled Trial of a Novel Metabolic Active Compound (Ranolazine) in Chronic Stable Angina Patients

C. Pepine, T. Parker, W. T. Garland, 1995 .

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

F. Hodi, G. Fine, O. Hamid, 2013 .

1322PBIOMARKERS ASSOCIATED WITH CLINICAL ACTIVITY OF PD-L1 BLOCKADE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE I STUDY OF MPDL3280A.

S. Gettinger, R. Heist, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.